Evaluate Pharma：2025年第一季度全球生物制药行业状况报告：压力之下（英文版）

The first quarter of the year got off to a predictably shaky start for a biopharma market which is marked by increasing uncertainty and turmoil. Huge cuts at the FDA, coupled with the will-they/won’t-they situation on tariffs for pharmaceutical players are making it hard for investors and dealmakers to make bold moves in almost any part of the industry